Markets:

Overview

News

Currencies

International

Treasuries

ADC Therapeutics SA Common Shares (NY:ADCT)

3.910 -0.140 (-3.46%)

Streaming Delayed Price Updated: 12:56 PM EDT, Mar 24, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about ADC Therapeutics SA Common Shares

< Previous 1 2 3 4 5 6 7 8 9 Next >

ADC Therapeutics Stock Is Plunging Today - What's Going On? ↗

July 11, 2023

ADC Therapeutics SA (NASDAQ: ADCT) has voluntarily paused enrollment of new patients in the Phase 2 LOTIS-9 trial evaluating Zynlonta (loncastuximab tesirine-lpyl) and rituximab (Lonca-R) in unfit or...

Via Benzinga

ADC Therapeutics Announces Voluntary Pause of Enrollment in the Phase 2 LOTIS-9 Clinical Trial of ZYNLONTA® (loncastuximab tesirine-lpyl) and Rituximab in Unfit or Frail Previously Untreated DLBCL Patients

July 11, 2023

From ADC Therapeutics SA

Via GlobeNewswire

ADC Therapeutics Announces Updated LOTIS-2 Results Demonstrating Durable, Long-Term Responses of ZYNLONTA® in Relapsed/Refractory DLBCL

June 09, 2023

Data being presented at the EHA 2023 Hybrid Congress will also be highlighted in an encore oral presentation at 17-ICML

From ADC Therapeutics SA

Via GlobeNewswire

Earnings Preview: ADC Therapeutics ↗

February 27, 2023

Via Benzinga

The Latest Analyst Ratings for ADC Therapeutics ↗

January 24, 2023

Via Benzinga

4 Analysts Have This to Say About ADC Therapeutics ↗

January 04, 2023

Via Benzinga

ADC Therapeutics to Participate in the Jefferies Healthcare Conference

June 01, 2023

From ADC Therapeutics SA

Via GlobeNewswire

ADC Therapeutics Announces Updated Results from LOTIS-2 Trial to be Presented at the European Hematology Association 2023 Hybrid Congress

May 11, 2023

From ADC Therapeutics SA

Via Business Wire

ADC Therapeutics to Participate in the RBC Capital Markets Global Healthcare Conference

May 10, 2023

From ADC Therapeutics SA

Via Business Wire

ADC Therapeutics Reports First Quarter 2023 Financial Results and Provides Business and Strategy Update

May 09, 2023

From ADC Therapeutics SA

Via Business Wire

ADC Therapeutics to Host First Quarter 2023 Financial Results Conference Call on May 9, 2023

May 02, 2023

From ADC Therapeutics SA

Via Business Wire

Benzinga's Top Ratings Upgrades, Downgrades For April 24, 2023 ↗

April 24, 2023

Via Benzinga

ADC Therapeutics Releases its Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2022

March 15, 2023

From ADC Therapeutics SA

Via Business Wire

Stocks That Hit 52-Week Lows On Tuesday ↗

March 21, 2023

On Tuesday, 74 companies achieved new lows for the year.

Via Benzinga

ADC Therapeutics to Participate in the Cowen 43rd Annual Health Care Conference

March 01, 2023

From ADC Therapeutics SA

Via Business Wire

Stocks That Hit 52-Week Lows On Tuesday ↗

March 14, 2023

Tuesday's morning session saw 84 companies set new 52-week lows.

Via Benzinga

ADC Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Updates

February 28, 2023

From ADC Therapeutics SA

Via Business Wire

ADC Therapeutics to Host Fourth Quarter and Year-End 2022 Financial Results Conference Call on February 28, 2023

February 21, 2023

From ADC Therapeutics SA

Via Business Wire

ADC Therapeutics Announces Pricing of Underwritten Offering by a Selling Shareholder

February 02, 2023

From ADC Therapeutics SA

Via Business Wire

ADC Therapeutics to Participate in February Investor Conferences

February 01, 2023

From ADC Therapeutics SA

Via Business Wire

Tesla And Other Big Stocks Moving Lower In Friday's Pre-Market Session ↗

January 13, 2023

U.S. stock futures traded mixed this morning. Here are some big stocks recording losses in today’s pre-market trading session.

Via Benzinga

Why KNOT Offshore Partners Shares Are Trading Lower By Around 38%? Here Are Other Stocks Moving In Thursday's Mid-Day Session ↗

January 12, 2023

Gainers BigBear.ai Holdings, Inc. (NYSE: BBAI) shares jumped 239% to $2.8715 after the company announced it has been awarded a multiple award $900 million Indefinite Delivery/Indefinite Quantity...

Via Benzinga

TSMC, CommScope Holding And Other Big Stocks Moving Higher On Thursday ↗

January 12, 2023

U.S. stocks traded higher, with the Dow Jones gaining around 150 points on Thursday. Here are some big stocks recording gains in today’s session.

Via Benzinga

ADC Therapeutics to Participate in the 41st Annual J.P. Morgan Healthcare Conference

January 04, 2023

From ADC Therapeutics SA

Via Business Wire

ADC Therapeutics Appoints Mohamed Zaki as Chief Medical Officer

January 03, 2023

From ADC Therapeutics SA

Via Business Wire

Nike, FedEx And Some Other Big Stocks Moving Higher In Today's Pre-Market Session ↗

December 21, 2022

U.S. stock futures traded higher this morning. Here are some big stocks recording gains in today’s pre-market trading session.

Via Benzinga

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday ↗

December 21, 2022

We're starting off the day with a breakdown of the biggest pre-market stock movers traders need to know about on Wednesday

Via InvestorPlace

Why Core Scientific Shares Are Trading Lower By Around 32%; Here Are 26 Stocks Moving Premarket ↗

December 21, 2022

Gainers ADC Therapeutics SA (NASDAQ: ADCT) shares rose 36.8% to $4.35 in pre-market trading. ADC Therapeutics and Sobi announced European Commission approval of ZYNLONTA for the treatment of relapsed...

Via Benzinga

ADC Therapeutics and Sobi Announce European Commission Approval of ZYNLONTA® (loncastuximab tesirine) for the Treatment of Relapsed or Refractory Diffuse Large B-cell Lymphoma

December 21, 2022

From ADC Therapeutics SA

Via Business Wire

ADC Therapeutics Appoints Jose Carmona as Chief Financial Officer

December 19, 2022

From ADC Therapeutics SA

Via Business Wire

< Previous 1 2 3 4 5 6 7 8 9 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.